Loading stock data…
MLTX
$16.73+0.35 (+2.14%)
Market ClosedLast close May 1
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MoonLake Immunotherapeutics in the Healthcare sector is trading at $16.73. The stock is currently near its 52-week low of $5.95, remaining 32.4% below its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why MLTX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.73
Potential Upside
5%
Whystock Fair Value$17.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$26.71+59.7%
Range$6.00 – $40.00
Fundamentals
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.86%
Volume
Today's trading volume
830,997
Recent News
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
Focused on novel immunotherapies for inflammatory diseases, this biotech firm reported significant insider selling in its latest filing.
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently reported long-term Week 40 results from its Phase 3 VELA-1 and VELA-2 trials in moderate-to-severe hidradenitis suppurativa, showing sustained clinical responses and quality-of-life improvements for patients treated with sonelokimab and no new safety signals. The company highlighted that sonelokimab’s Week 40 outcomes may set a new standard for long-term lesion control in hidradenitis suppurativa compared with existing IL-17-based treatments. Next, we’ll...
MoonLake’s lead asset shows durability in late-stage HS studies
Analysts note that treatment durability is a key unmet need in HS, and will define a drug’s commercial success on the market.
MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says
MoonLake Immunotherapeutics (MLTX) reported 40-week data from its phase 3 VELA-1 and VELA-2 studies